1. Introduction {#sec1}
===============

Cell-based strategies are widely used for tissue engineering purposes, that is, to achieve the replacement, repair, and restoration of tissue and organ functions. Somatic stem cells, especially mesenchymal stromal cells (MSCs), represent the most valuable resource to this aim, being mainly used in orthopedics applications \[[@B27], [@B44]\]. MSCs, originally isolated from bone marrow, are multipotent cells, residing in the connective stroma of different adult tissues and solid organs, and capable to differentiate toward multiple mesodermal lineages \[[@B50]\]. MSCs can be indeed isolated from different adult tissues sources, including fat, skeletal muscle and skin \[[@B50]--[@B41]\]. Beside adult tissues, more recently MSC have been isolated from fetal and perinatal fluids and tissues, including umbilical cord (UC), chorionic villi (CV), and amniotic fluid (AF) \[[@B17]--[@B8]\]. Particularly, amniotic fluid stromal cells (AFSCs) can be regarded as attractive pluripotent stem cells, due to the ease of isolation from small volumes of AF, their rapid expansion in culture and their capability of extensive self-renewal \[[@B8]--[@B53]\]. In addition, AFSCs appear phenotypically and genetically stable after *in vitro* expansion, overcoming all the safety issues related to the use of embryonic/fetal cells \[[@B48]\]. The surface marker profile of AFSC suggests that they represent an intermediate stage between embryonic stem cells and adult MSC \[[@B8], [@B23]\]. In fact, AFSC retain the ability to differentiate into cells of all three embryonic germ layers along with higher growth kinetics than adult MSC \[[@B50], [@B42], [@B53], [@B18]\]. These features makes AFSCs unique among somatic stem cells and suggests their possibile application in translational medicine, by-passing the common ethical issues associated to embryonic stem cells.

Among the wide range of tested clinical applications of AFSCs \[[@B54]\], their osteogenic potential has been particularly investigated as a potentially relevant property, in the light of the attractive results obtained in animal models of skeletal regeneration (\[[@B60]--[@B43]\]). The complete network of molecular signals involved in the osteogenic commitment of MSCs has been partially defined. We have previously demonstrated that the Kruppel-like factor family genes coding for DNA-binding proteins play a crucial role in maintaining MSC stemness and self-renewal properties by transcription regulation and are progressively repressed during MSC differentiation \[[@B51]\].

The LIM mineralization protein (LMP) is an intracellular positive regulator of osteoblast differentiation that is able to induce the osteogenic differentiation of MSC, by activating the expression of genes that govern the balance between cell proliferation/differentiation and are involved in skeletal tissue development \[[@B1], [@B47]\]. LMP was originally isolated from the rat calvaria and is present in three alternatively spliced transcript variants, namely, LMP-1, -2, and -3, in humans (GenBank accession numbers: AAK30567.1; AAK30568.1, AAK30569.1, respectively, \[[@B3], [@B4]\]. The first two transcript variants, LMP1 and LMP2, encoding the full-length and intermediate protein isoforms, respectively, contain both PDZ and LIM conserved domains in their structure. LMP3 encode a truncated isoform and represent the shortest variant \[[@B33]\]. Both LMP1 and LMP3 are osteogenic and could represent promising molecular tools for bone tissue-engineering applications, as recent studies demonstrated that they act upstream to the main osteogenic pathways \[[@B27], [@B1], [@B47], [@B49]\]. In particular, the most functionally relevant molecular interactions involved in the LMP1 osteogenic properties have been clarified *in vitro*, while the LMP3-related osteogenic signalling is still poorly understood.

The aim of this study was to assess the capability of LMP3 to induce the osteogenic differentiation of AFSCs, and to characterize the molecular events associated to this process, focusing on the molecular features underlying the multipotency/differentiation switch.

2. Materials and Methods {#sec2}
========================

2.1. Cell Isolation and Culture {#sec2.1}
-------------------------------

Amniotic fluid samples were obtained by amniocentesis performed between 16 and 20 weeks of gestation for fetal karyotyping. Patients were enrolled in the study upon signing a written informed consent. All procedures employed in this study have been approved by the Ethical Committee of the Catholic University of Rome, Italy (protocol number P552 (A.779/CE2007).

AFSCs were isolated from the diagnostic specimens using a two-step culture protocol, saving the amniocytes needed for chromosome analysis \[[@B50], [@B58]\]. Briefly, nonadherent cells were collected by centrifugation from the culture medium saved from amniocytes after 7 days of primary culture. Cells were then plated in T25 tissue culture flasks at a seeding density of 10^5^ cells/cm^2^, using the Mesenchymal Stem Cell Medium (MSCGM) (Lonza, Basel, Switzerland), and incubated overnight in a humidified incubator at 37°C and 5% CO~2~. The following day, the medium was replaced to remove nonadherent cells. Upon reaching 80% confluence, cells were detached with trypsin/EDTA and further expanded. The specific surface antigens of MSCs expressed on AFSC (at culture passage 4 to 5) were investigated by flow cytometry analysis, as previously described \[[@B50]\].

2.2. Adenoviral-Mediated Cell Transduction {#sec2.2}
------------------------------------------

Defective adenoviral vectors carrying the LMP-3 gene (AdLMP-3) were constructed as previously described \[[@B47]\]. Subconfluent AFSCs were transduced within the 3rd culture passage with 100 pfu/cell of AdLMP-3 vector. Mock-transfected cells, that is, cells infected with an empty adenoviral vector (the viral vector backbone, termed AdΨ5), served as negative transduction controls. Transduction efficiency was evaluated by means of RT-PCR as already described elsewhere \[[@B27]\]. Ad-transduced cells were then used in time-course experiments aimed at analyzing the expression of selected genes and studying the morphological modifications induced by LMP3 overexpression.

2.3. **In-Vitro** Mineralization Assay {#sec2.3}
--------------------------------------

To evaluate the occurrence of osteogenic commitment and differentiation of cells upon LMP3 overexpression, AFSCs were alternatively transfected with either AdLMP-3 or AdΨ5. AFSCs cultured in an osteogenic medium (OM, see \[[@B50]\] for protocol details) served as positive controls for *in vitro* differentiation and qPCR. Osteogenic differentiation was assessed after 2 weeks by alizarin red staining, as previously described \[[@B50]\].

2.4. RNA Isolation {#sec2.4}
------------------

The total RNA was isolated from both AdLMP3- amd AdΨ5-transduced AFSCs, at 1, 2, 4, and 7 days post-transduction, and from positive control cells following 2 and 7 days of osteogenic induction, using the RNeasy mini kit (Qiagen, Hilden, Germany), according to the manufacturer\'s suggested procedures. An additional on-column DNase incubation step was performed, allowing the selective removal of genomic DNA during the isolation process. RNA was quantified using a UV spectrophotometer and RNA quality and integrity were assessed Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA, USA). One microgram of RNA was reverse transcribed into cDNA using the Superscript III (Invitrogen, Carlsbad, CA, USA).

2.5. Gene Expression Analysis {#sec2.5}
-----------------------------

In order to clarify the molecular events underlying the LMP3-mediated AFSC differentiation, we have selected downstream acting genes involved in the differentiation process and analyzed their expression using quantitative real time PCR. In particular, we have focused on the osteospecific transcription factors, Runt-related transcription factor 2 (RUNX2) and Osterix (OSX), and on the osteospecific genes bone morphogenetic protein 2 (BMP2), Osteocalcin (OC), and Osteopontin (OP). In addition, we have analyzed the expression of the SWI/SNF-related, matrix associated, actin-dependent regulator of chromatin, C2 (SMARCC2). This gene encodes a protein member of the chromatin remodeling complex, which was involved in the osteogenic commitment of MSCs \[[@B66]\] and was selected based on previous data suggesting that the LMP3 could directly induce its expression in MSCs (Lattanzi et al., unpublished observation). In addition, in order to assess if LMP3 could alter the molecular control of stem cell self-renewal and maintenance, we have analyzed the expression of the Kruppel-like factor genes KLF-2 and KLF-4 \[[@B51], [@B30], [@B40]\].

Gene expression was analysed in transduced and control cells 1, 2, 4, and 7 days after adenoviral transduction, using quantitative real-time PCR. The assays were carried out in triplicate using *Power SYBR Green PCR Master Mix*(Applied Biosystems, Foster city, CA, USA), on a *StepOne* instrument (Applied Biosystems, Foster city, CA, USA). Thermocycling conditions were as follows: an initial denaturation step at 95°C for 20 sec followed by 40 cycles at 95°C for 1 sec and 60°C for 20 sec (annealing and extension). Primer sequences were designed using the Primer3 software (<http://frodo.wi.mit.edu/primer3/>) and reported in [Table 1](#tab1){ref-type="table"}. The 2^*‒*ΔΔ*Ct*^ method \[[@B34]\] was applied to calculate fold differences (fold change, FC) in gene expression, using the gene Actin-beta (B-ACT) as the housekeeping reference for data normalization. PCR products were subjected to melting curve analysis to rule out the synthesis of unspecific products.

2.6. LMP Transient Silencing {#sec2.6}
----------------------------

In order to clarify the influence of LMP on KLF-2 and -4 transcriptional modulation, LMP expression was silenced in AFSCs using a specific custom-designed double-strand small interfering RNA (siRNA) construct (QIAGEN, Hilden, Germany). The sequence of the anti-LMP siRNA construct was as follows: 5′-ATGCGGGTAGCCTCACACACA-3′, aligning on LMP gene sequence from base position 170 to 190. For the silencing assay, AFSCs were plated in 24 well plates at a density of 2 × 10^4^ cells/well and incubated under standard growth conditions. On next day, cells were transfected with LMP-siRNA construct, complexed with Lipofectamine RNAiMAX transfection reagent (Invitrogen, Carlsbad, CA, USA), according to the manifacturer\'s suggested procedure. Briefly, 0.5 *μ*g of siRNA construct were diluted in culture medium, thereafter, 1/10 volume of Lipofectamine RNAiMAX was added to the diluted siRNA and incubated for 10--15 minutes at room temperature. The complexes were diluted in 700 *μ*L of fresh culture medium and added to adherent cells. AFSCs transfected with a cocktail of negative control siRNA constructs (AllStars Negative Control siRNA, Qiagen) and cells treated with transfection reagent alone served as gene silencing sham and scramble controls, respectively. All experiments were carried out in triplicate in order to test the reproducibility.

The silencing efficiency of siRNA construct was evaluated by quantifying the expression of LMP gene in qPCR (see [Section 2.5](#sec2.5){ref-type="sec"}) 24 and 48 hours following cell transfection. The expression of KLF genes was also analyzed at the same time points.

2.7. Detection of miR143/145 {#sec2.7}
----------------------------

In order to investigate the relation between TGF*β*-1 and KLF4 during the LMP3-mediated osteogenic commitment, the expression levels of miR143/145 were analyzed in AdLMP3 transduced AFSCs, using untransduced cells and AdΨ5 mock-transduced cells as controls.

For this purpose, total RNA was isolated 24 and 48 hours after transfection with Ad-LMP3 and Ad-Ψ5, using the *mir*Vana miRNA Isolation Kit (Ambion, Austin, TX, USA), following the manifacturer\'s suggested procedure for small RNAs enrichment. RNA was quantified using a UV spectrophotometer. 0.5 *μ*g of RNA was then reverse transcribed using the miScript Reverse Transcription Kit (QIAGEN).

The expression levels of miR143 and miR145 were analyzed using the miScript SYBR Green PCR Kit and miScript Primer Assays (QIAGEN, Hilden, Germany). Six control miRNA, included in the miScript PCR Control Set (QIAGEN), were amplified in real time PCR, as reference controls for data normalization. The real-time PCR reaction was carried out on the StepOne instrument (Applied Biosystems, Foster city, CA, USA), using the following thermocycling conditions: an initial activation step at 95°C for 15 min followed by 40 cycles at 94°C for 15 sec, 55°C for 30 sec, and 70°C for 30 sec (denaturation, annealing and extension). The 2^*‒*ΔΔ*Ct*^ method \[[@B34]\] was applied to calculate fold differences in gene expression as previously described (see [Section 2.5](#sec2.5){ref-type="sec"}). PCR products were subjected to melting curve analysis to rule out the synthesis of unspecific products.

3. Results {#sec3}
==========

3.1. Isolation and Characterization of AFMSCs {#sec3.1}
---------------------------------------------

Adherent cells were efficiently isolated from AF as soon as 2-to-5 days after sample plating. The primary cellular population was heterogeneous, with elongated thin cells and flat rounded cells. Upon the first passage, all cells displayed a homogeneous adherent fibroblast-like morphology, being bipolar, spindle-shaped cells. The cells exhibited a homogenous "mesenchymal" immunophenotype: CD73+, CD90+, CD133+, cKit-.

3.2. hLMP-3 Gene Transfer Induces Osteogenic Differentiation of AFSCs **In Vitro** {#sec3.2}
----------------------------------------------------------------------------------

The transduction efficiency was evaluated by means of RT-PCR to measure the transgenic LMP3 expression, using sequence-specific oligonucleotide primers. An intense PCR band of the expected size was observed at each tested time point in cells transduced with AdLMP3, indicating an efficient and stable transgene expression ([Figure 1](#fig1){ref-type="fig"}).

Alizarin staining was used to assess the osteogenic differentiation *in vitro* in AFSC overexpressing LMP3 compared to mock-transduced cells. Two weeks after AdLMP3 transduction, AFSC produced a diffuse red-stained mineralized matrix, as demonstrated by alizarin red staining ([Figure 2(a)](#fig2){ref-type="fig"}). Cells cultured in OM displayed a comparable degree of matrix mineralization *in vitro*(data not shown). Conversely, no evident signs of osteogenic differentiation were observed in mock transduced cells at the same tested time point ([Figure 2(b)](#fig2){ref-type="fig"}).

3.3. LMP-3 Induces the Osteogenic Differentiation of AFSCs by Inactivation of KLF Genes and Further Upregulation of Osteospecific Transcription Factors and Bone Marker Genes {#sec3.3}
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

In order to investigate the molecular effects of LMP3-mediated bone induction, we examined the expression level of genes associated with stemness maintenance and osteoblastic reprogramming. The analysis revealed that LMP-3 induced a significant and time-related upregulation of osteospecific markers. In particular, the level of BMP2, increased 2.5 folds (*P* \< 0.05) and more than 10 folds (*P* \< 0.05) in Ad-LMP3 transduced compared to AdΨ5-treated cells, at day 4 and 7 after transduction, respectively. No significant modulation of BMP2 expression was observed at the earliest tested time points (day 1 and day 2; [Figure 3(a)](#fig3){ref-type="fig"}). Interestingly, the expression of BMP2 in cells treated for 7 days with the OM (FC: 4.9; *P* \< 0.05) was lower than that induced by LMP3 (FC: 10.9; *P* \< 0.05). No significant modulation of BMP2 expression was observed in cells cultured in OM at the earliest time points ([Figure 3(a)](#fig3){ref-type="fig"}). RunX2 was significantly (*P* \< 0.05) upregulated in both OM-treated and LMP3-overexpressing cells, compared to control mock-transfected ones, from day 2 on. Conversely, no signficant modulation was observed at day 1 ([Figure 3(b)](#fig3){ref-type="fig"}). Particularly, at day 7, also in this case, a higher upregulation (FC: 9.8; *P* \< 0.05) was observed at day 7 in LMP3-transfected cells, compared to OM-treated cells (FC: 6; *P* \< 0.05; [Figure 3(b)](#fig3){ref-type="fig"}). Also, the SMARCC2 gene resulted significantly upregulated from day 2 on, in both OM-treated cells and AdLMP-3 overexpressing ones ([Figure 3(c)](#fig3){ref-type="fig"}). In particular, the increase in SMARCC2 gene expression showed a time-related trend in the AdLMP-3 group and reached the highest value (*FC* \> 20; *P* \< 0.05[Figure 3(c)](#fig3){ref-type="fig"}) at day 7, when it was 4-fold higher than in the OM group ([Figure 3(c)](#fig3){ref-type="fig"}). The OC gene expression did not vary at either day 1 or day 2, in any experimental group while increased significantly in AdLMP-3-transduced cells at day 4 (FC: 2.2, *P* \< 0.05) and day 7 (FC: 5.4, *P* \< 0.05; [Figure 3(d)](#fig3){ref-type="fig"}). Interestingly, no significant modulation in OC expression was induced in cells induced for 7 days in OM ([Figure 3(d)](#fig3){ref-type="fig"}). The transcription factor OSX was significantly upregulated, from day 2 on, in all treatment groups compared to AdΨ5-treated cells, but displayed a different trend of gene expression, with higher fold changes in the OM-treated than in the LMP3-overexpressing groups, at all tested time points ([Figure 3(e)](#fig3){ref-type="fig"}). Finally, the OP gene resulted significantly upregulated exclusively at day 7 (FC: 4.4; *P* \< 0.05) in AFSCs transduced with AdLMP-3 ([Figure 3(f)](#fig3){ref-type="fig"}).

LMP-3 overexpression in AFSCs was able to modulate the expression of the Kruppel-like factors (KLF) genes. In particular, a slight (less than 40% decrease) but significant downregulation of both KLF4 (FC: 0.63; *P* \< 0.05) and KLF2 (FC: 0.68; *P* \< 0.05) was observed as early as 24 hours post-transduction. Thereafter, a higher fold change decrease of KLF genes\' expression was observed in AFSCs 2, 4, and 7 days after AdLMP3 transduction ([Figure 4(a)](#fig4){ref-type="fig"}). In particular, KLF4 expression was reduced by more than 80% in both the day 2 and the day 4 groups (FC: 0.22 and 0.23, resp.; [Figure 4(a)](#fig4){ref-type="fig"}). A lesser extent of gene downregulation (FC: 0.59, i.e., around 40% decrease) was then observed after 7 days. Conversely, the expression of KLF2 showed a time-related trend as its expression levels decreased gradually throughout the time course ([Figure 4(a)](#fig4){ref-type="fig"}).

3.4. LMP Silencing Induces KLF4 Upregulation {#sec3.4}
--------------------------------------------

In order to verify the direct regulatory effects of LMP on KLF-2 and -4, during the activation of the osteogenic cascade, the expression of LMP gene has been transiently inhibited in AFSCs. LMP silencing was efficient as gene expression was significantly reduced by 55% (FC: 0.45) and 70% (FC: 0.26) 24 and 48 hours, respectively, after siRNA transfection ([Figure 5(a)](#fig5){ref-type="fig"}). The expression levels of KLF genes in LMP-silenced AFSC was transiently modulated 24 hours after LMP silencing. In particular, only the expression of KLF4 was significantly (FC: 1.58; *P* \< 0.05) upregulated in AFSCs, while no significant change in KLF2 expression was observed ([Figure 5(b)](#fig5){ref-type="fig"}). Thereafter, expression of both KLF genes was not signficantly modified 48 hours after siRNA treatment compared to controls (data not shown).

3.5. LMP3 Overexpression Does Not Induce the miR-143/145 Signaling {#sec3.5}
------------------------------------------------------------------

In order to verify the possible involvement of the miR-143/145 cluster activation, in the LMP3-mediated KLF4 repression, we have analyzed the expression of the two microRNA in Ad-LMP3 transduced cells, 24 and 48 hours post-transduction, using untransduced and AdΨ5-transduced cells as controls. Our results showed that miR-145 was undetectable in AFSC in all experimental groups up to 48 hours posttransfection. miR-143 was weakly expressed in all experimental conditions only at 48 hours, but no significant differential expression was observed between AdLMP3-treated cells and controls ([Figure 4(b)](#fig4){ref-type="fig"}).

4. Discussion {#sec4}
=============

Since their original isolation from rat calvarial bone in 1998 \[[@B3]\], lim mineralization proteins (LMPs) have been employed to induce bone formation/healing in diverse animal models along with the osteogenic differentiation of mesoderm-derived cell types *in vitro* \[[@B27], [@B44], [@B47], [@B4], [@B59]--[@B38]\]. Three alternative transcript variants are spliced from the same human gene (PDZ and LIM domain 7 (enigma), PDLIM7) giving rise to three protein isoforms, namely, LMP1, LMP2, and LMP3 ([Figure 6(a)](#fig6){ref-type="fig"}). Although the proteins are named after the presence of LIM conserved domains, these are present in only LMP1 and LMP2 isoforms; while the PDZ domain is present in all the three variants \[[@B33]\]. LIM domains are supposed not to be required for the osteogenic properties of LMP, considering that the osteogenic properties have been demonstrated only for LMP1 and LMP3 \[[@B33], [@B49]\]. The nonconserved region of the human LMP1 protein is represented by a 300-aminoacid sequence ([Figure 6(a)](#fig6){ref-type="fig"}). This domain is only partially retained in LMP3, due to the alternative splicing process that causes the out-of-frame insertion of 17bp causing the introduction of a premature stop codon \[[@B47]\]. The resulting protein shares the first 133 aminoacids with LMP1, while is different in the C-terminus. The full-length isoform (LMP1, [Figure 6(a)](#fig6){ref-type="fig"}) is known to induce the expression of BMP and reinforce the osteogenic effect of exogenous BMPs during ectopic bone formation \[[@B65], [@B38]\]). LMP3 has been shown to induce ectopic bone formation in mice, following either direct vector-mediated gene transfer or using cell-based delivery, along with efficient bone healing in a rat mandibular bone defect model \[[@B27], [@B44], [@B47]\]. The molecular mechanisms underlying LMP3 function have been partially elucidated, by analyzing the consequences of transgenic expression in rodent cells, including calvarial osteoblasts, murine preosteoblasts and dermal fibroblasts \[[@B27], [@B47]\]. These studies allowed demonstrating that the molecular signaling initiated by LMP3 tends to overlap with and amplify the BMP2-induced osteogenic cascade, through the direct upregulation of both BMP2 and its bone-specific target genes \[[@B47], [@B33]\]. We have recently shown that the early phases of the molecular signaling induced by LMP3 in human bone marrow-MSCs involve the activation of the transforming growth factor *β*1 pathway, leading to the regulation of cell proliferation and the induction of muscular-skeletal tissue differentiation \[[@B1]\]. Taken together, these data could suggest that LMP3 acts upstream to the main osteogenic developmental signaling pathways.

In this study, we have further demonstrated that LMP3 can induce the efficient osteogenic differentiation of mesenchymal cells isolated from amniotic fluid (AFSCs). Along with other fetal tissues\' derived MSCs, AFSCs display more "undifferentiated" features \[[@B50]\]. Recent data have indicated that induced pluripotent stem cells (iPS) are more efficiently generated from AF-derived cells rather than from human somatic cells \[[@B13]\]. Thus, this cell type could represent a suitable *in vitro* model for characterizing the basic molecular events associated to the LMP-induced osteogenic cell differentiation program \[[@B50], [@B8]--[@B53]\]. Our results demonstrated that in AFSCs LMP3 induces a significant and early transcriptional activation of SMARCC2, along with BMP2, OC, OP, and the bone-specific transcription factors RUNX2 (CBFA1) and OSX. SMARCC2 encodes a poorly characterized member of the SWI/SNF chromatin remodeling complex necessary for the osteogenic differentiation of mesenchymal cells trough the BMP2/RunX2 pathway \[[@B66]\]. The effects of LMP3 on BMP2, RUNX2, and SMARCC2 gene expression was even stronger than those induced by the standard osteogenic induction in AFSC cultures. Based on previous observations, it could be speculated that the overexpression of LMP3 gene tends to amplify the downstream effects on target genes, through the activation of the TGF*β* and BMP2 osteogenic pathways \[[@B27], [@B1]\], [Figure 6(b)](#fig6){ref-type="fig"}).

Our results also showed that LMP3 displays an inhibitory effect on KLF-4 gene expression. KLF genes encode a subclass of the zinc-finger family of transcription factors implicated in the regulation of cell growth and differentiation, acting on the cell cycle checkpoints \[[@B51], [@B30], [@B40]\]. Particularly, KLF4 is implicated in maintaining stem cells in an undifferentiated status and is able to mediate cancer cells proliferation, migration, and invasion \[[@B30], [@B40], [@B67]\]. The combination of KLF4 with other core-transcription factors (namely OCT4, SOX2, and c-MYC) define the "OSKM" gene network, widely used for reprogramming somatic cell and generate iPS \[[@B57]--[@B36]\]. We have recently demonstrated a role of KLF4 in defining the gene expression signature associated to MSC stemness maintenance \[[@B51]\]. Although a specific role for KLF4 in AFSC biology and homeostasis has not been yet demonstrated, the possibility of efficiently inducing iPS from amniotic fluid-derived cells through OSKM gene overexpression could reasonably corroborate this hypothesis \[[@B13], [@B29], [@B35]\].

KLF4 was also found to be implicated in the TGF*β*-dependent regulation of smooth muscle cell differentiation; TGF*β* downregulates KLF4, which, on its turn, represses the TGF *β*-dependent increase in differentiation markers \[[@B24]--[@B69]\]. In the same cells, KLF4 was also found to induce the expression of the TGF*β* receptor I and the activation of Smad2/3---p38 MAPK signaling, suggesting the existence of a feed-back loop implicated in the cell differentiation program \[[@B71]\]. Based on such evidences, the KLF4 downregulation described in this study could be considered among the basic molecular effects induced by LMP3 during the osteogenic commitment of AFSCs. Infact, upon LMP silencing, KLF4 expression transiently increased, suggesting that the osteogenic effects of LMP on AFSCs could be mediated, at least in part, by the inhibition of KLF4. We have previously shown that LMP3 induces the early transcriptional activation of TGF*β*1 and related signaling pathway \[[@B1]\], which is known to underlie osteoblast differentiation of MSC \[[@B26]\]. Taken together, these data could suggest that LMP3-mediated osteogenic signaling implies the induction of TGF *β*1 that, on its turn, may induce KLF4 downregulation. It was recently demonstrated that TGF*β* induces KLF4 repression through the transcriptional activation of two microRNAs (miR-143/miR145), during the terminal differentiation of vascular smooth muscle cells \[[@B7]\]. No data so far described the possible involvement of the TGF*β*-miR143/145-KLF4 pathway in the molecular network underlying the osteogenic process. Our results indicated that mir143/145 were not involved in the LMP3-mediated KLF4 modulation, suggesting that an alternative pathway should be activated during the osteogenic commitment of AFSC.

Interestingly, no significant modulation of BMP2, RUNX2 and OSX gene expression occurred among the early molecular events induced by LMP3 overexpression in AFSC. This evidence is coherent with the early molecular profile observed in bone-marrow-derived MSC transduced with AdLMP3 \[[@B1]\]. This evidence may suggest that the activation of the TGF*β* cascade is initiated by LMP through a BMP2-independent mechanism, which may deserve further close examination.

The longer LMP isoform, LMP1, was recently described as a downstream target gene of TGF*β*1, essential for the proliferation and differentiation of periodontal ligament progenitor cells \[[@B31]\]. These evidences may suggest the existence of a reciprocal feedback control between LMP molecules and TGF*β*1 during cell replication and/or differentiation that may also implicate the transcriptional modulation of KLF4. Based on such observations, a clearer insight into the LMP3-TGF interaction should be obtained in further studies, in order to delineate the correct molecular steps involved in the LMP-dependent osteogenic cascade.

Our results showed also that another KLF gene, KLF2, was apparently modulated during LMP3-induced osteogenic differentiation of AFSC, although it was not significantly modulated following LMP silencing. This suggested that KLF2 should not be directly regulated at the transcriptional level by LMP. KLF2 is one of the core transcription factors implicated in embryonic stem cells maintenance, self-renewal and pluripotency \[[@B20]--[@B12]\]. It has been recently demonstrated that KLF2 inhibits adipogenesis and monocyte differentiation \[[@B28]--[@B6]\] and governs specific developmental steps in different tissues \[[@B37], [@B63]\]. Although no clear evidence has suggested so far that KLF2 may affect osteogenic differentiation, it could be hypothesized that the KLF2 downregulation observed in LMP-overexpressing AFSCs could be a consequence of the cell differentiation process.

5. Conclusions {#sec5}
==============

This study proposes some additional hints towards the functional characterization of LMP, which only recently emerged as an efficient osteogenic molecule. Based on the original data obtained in this study, the involvement of an alternative signaling, within the osteogenic cascade induced by LMP, could be assumed. This hypothesis may deserve *ad hoc* further investigations. Considering the easy retrieval of AFSCs and the lack of major invasiveness and ethical issues of the proposed isolation protocol, these results could provide a convincing proof-of-principle for the potential development of future autologous cell-based therapies based on these cells, to be employed for bone regeneration/healing purposes also in perinatal applications.
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![Transduction efficiency. RT-PCR showing transgenic LMP-3 expression (visible bands) up to 72 hours after cell transduction. No transgene expression can be detected in the control cells transduced with AdΨ5.](JBB2012-813894.001){#fig1}

![Osteogenic differentiation *in vitro.* Alizarin Red staining performed 2 weeks after cell transduction, showing a red-colored mineralized matrix in treated cells ((a) AdLMP-3) and negative staining in control cells ((b) AdΨ5).](JBB2012-813894.002){#fig2}

![qPCR gene expression analysis. The graphic represents the expression levels of osteospecific gene ((a) BMP2; (b) RunX2; (c) SMARCC2; (d) OC; (e) OSX; (f) OP). Values represent the mean of triplicate experiments for each time point tested. AdΨ5: mock-transduced control cells; AdLMP-3: treated cells; OM: cells cultivated in osteogenic medium as positive controls; d: days after cell transduction (4d-time point was not assessed in OM-cells); \*: statistical significance, *P* \< 0.05. Fold change was calculated according to the 2^*‒*ΔΔ*Ct*^ method.](JBB2012-813894.003){#fig3}

![KLF genes expression analysis. Values represent the mean of triplicate experiments for each time point tested, namely, 2, 4, and 7 days after AdLMP3-mediated cell transduction; Ψ5: control sample represented by mock-transduced cells. Fold change was calculated according to the 2^*‒*ΔΔ*Ct*^ method. \*: statistical significance (*P* \< 0.05).](JBB2012-813894.004){#fig4}

![Gene expression analysis upon LMP silencing. The histogram represents the relative expression levels of LMP (24 and 48 hours following siRNA transfection, (a)), KLF2 and KLF4 (24 hours after LMP silencing, (b)). Values represent the mean of triplicate experiments for each test. SHAM: cells treated with transfection reagent alone; Neg Ctrl: cells transfected with AllStars Negative Control SiRNA; SiRNA-LMP: cells treated with SiRNA-LMP construct; RQ: relative quantity, calculated according to 2^*‒*ΔΔ*Ct*^ method; \*: statistically significant (*P* \< 0.01).](JBB2012-813894.005){#fig5}

![LMP domains and hypothetical signaling pathway.LMP1 and LMP3 are the osteogenic isoforms resulting from the alternative splicing of the PDLIM7 gene. (a) Both proteins share a conserved PDZ domain and a supposed osteogenic region which comprises two separate domains which interact with the SMURF1 WW2 domain (Sangadala et al, 2006). Three conserved LIM domains are present in the C-terminus of LMP1 while are absent in LMP3 due to its premature termination as a consequence of an out-of-frame insertion during splicing (see text for details). A scheme of the hypothetic molecular signaling induced by LMP3 in AFSC is proposed in (b) LMP3 induces the expression of the osteogenic transcription factors OSX and RUNX2, along with the osteogenic markers OC and OP. SMARCC2, involved in chromatin remodeling, is also a transcriptional target of LMP3, according to our results. LMP3 upregulates BMP2 that, on its turn, binds its surface receptor. This event induces the activating phosphorilation of SMADs that translocate to the nucleus to induce RUNX2, leading to the transcriptional induction of bone-specific genes mediating the osteogenic cascade. Conversely the KLF4 transcription factor is downregulated by LMP3. Also TGF*β*, induced by LMP3 in bone marrow-derived MSCs (Bernardini et al, 2010) represses KLF4 expression, by inducing the miR143-145 cluster (Davis-Dusenbery et al, 2011), which resulted unaffected by LMP3 overexpression. A + sign inducate positive regulation, a -- sign indicate negative regulation on the arrows and lines; EC: extracellular compartment.](JBB2012-813894.006){#fig6}

###### 

Sequences of oligonucleotide primer used in qPCR.

  Gene symbol   Sense^∗^                          Sequence
  ------------- --------------------------------- ---------------------------------
  B-ACT         Fw                                5^′^-TCGTGCGTGACATTAAGGAG-3^′^
  Rv            5^′^-CCATCTCTTGCTCGAAGTCC-3^′^    
  BMP2          Fw                                5^′^-CGTGTCCCCGCGTGCTTCTT-3^′^
  Rv            5^′^-CGGCCACCATGGTCGACCTT-3^′^    
  KLF2          Fw                                5^′^-GGCTTGTGATGCCTTGTGA-3^′^
  Rv            5^′^-TGCCCACCTGTCTCTCTATGT-3^′^   
  KLF4          Fw                                5^′^-GACCACCTCGCCTTACACAT-3^′^
  Rv            5^′^-CCCCCAACTCACGGATATAA-3^′^    
  LMP           Fw                                5^′^-AGCATCGATGGCGAGAAT-3^′^
  Rv            5^′^-CCGGATCTTGTTCTGAGCTT-3^′^    
  OC            Fw                                5^′^-GACTGTGACGAGTTGGCTGA-3^′^
  Rv            5^′^-AGCAGAGCGACACCCTAGAC-3^′^    
  OP            Fw                                5^′^-TGAAACGAGTCAGCTGGATG- 3^′^
  Rv            5^′^-GCTCTCATCATTGGCTTTCC-3^′^    
  OSX           Fw                                5^′^-TAGACACCATGACCCCATCA-3^′^
  Rv            5^′^-CATGGCAACAGGGGATTAAC-3^′^    
  RunX2         Fw                                5^′^-GATGTGCCTAGGCGCATT-3^\'^
  Rv            5^′^-AAAAGGGCCCAGTTCTGA-3^′^      
  SMARCC2       Fw                                5^′^-CAGACATCTCTCCCCCTCAC-3^′^
  Rv            5^′^-CTGGAACCGTGATGTCCAC-3^′^     

^∗^: Fw: forward (left) primer; Rv: reverse (right) primer.

[^1]: Academic Editor: Thomas Lufkin
